Human RCTPubMed ID: 34234942·2021

SURPASS-3: Tirzepatide Efficacy with Concurrent Insulin

Grunberger G, Doyle ME, Soto A, et al.

Diabetes Care, 2021 · n = 631

Key finding

Tirzepatide 15mg reduced HbA1c by 1.9% versus insulin placebo by 0.3% (p<0.001); improved weight by 2.9kg versus 1.5kg gain with insulin alone.

Summary

Phase 3 trial of tirzepatide as add-on to insulin therapy in type 2 diabetes patients.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

TirzepatideL5

An FDA-approved dual GIP/GLP-1 receptor agonist that has shown the highest weight loss results of any approved medication.

More research on Tirzepatide

Tirzepatide vs Semaglutide Once Weekly for Weight Management (SURMOUNT-5)

New England Journal of Medicine · 2024 · Human RCT

Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2)

The Lancet · 2023 · Human RCT

Tirzepatide for Weight Management after Lifestyle Intervention (SURMOUNT-3)

Nature Medicine · 2023 · Human RCT

SURPASS-4: Tirzepatide Cardiovascular Outcomes Trial

New England Journal of Medicine · 2023 · Human RCT

Tirzepatide Reduces Sleep Apnea Severity in Obesity

Sleep Medicine Reviews · 2023 · Human Pilot